Biocryst Pharmaceuticals (BCRX) Net Equity Issued and Repurchased (2012 - 2021)

Biocryst Pharmaceuticals' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at $50.0 million for Q4 2021.

• Quarterly Net Equity Issued and Repurchased rose 11500.93% year-over-year to $50.0 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $50.4 million (down 14.42% YoY) and the FY2021 annual result came in at $50.0 million, down 46.4% from the prior year.
• Net Equity Issued and Repurchased was $50.0 million for Q4 2021 at Biocryst Pharmaceuticals, up from $431000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $86.2 million in Q3 2017 and bottomed at $431000.0 in Q4 2020.
• A 4-year average of $40.6 million and a median of $48.9 million in 2017 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased tumbled 99.26% — and 2021, when it jumped 11500.93%.
• Biocryst Pharmaceuticals' Net Equity Issued and Repurchased stood at $500000.0 in 2017, then soared by 11600.0% to $58.5 million in 2019, then tumbled by 99.26% to $431000.0 in 2020, then soared by 11500.93% to $50.0 million in 2021.
• Business Quant data shows BCRX's Net Equity Issued and Repurchased at $50.0 million in Q4 2021, $431000.0 in Q4 2020, and $58.5 million in Q4 2019.